THERAPY DOSSIER · th-831278919ca8

Magnesium chenoursodeoxycholic acid (Mg-CUD)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21284943 ↗2011Reported benefit

Protective effects of Mg-CUD against D-galactosamine-induced hepatotoxicity in rats.

RatChemical/toxinSprague-DawleyMaleOral15.625, 31.25 and 62.5 mg/kgOnce daily for 2 weeks and 6 h after D-GalN injection

Model: D-galactosamine-induced acute liver injury (700 mg/kg intraperitoneal)

Mg-CUD ameliorated D-galactosamine-induced acute hepatitis through antioxidative and anti-inflammatory effects and inhibition of NF-kappaB activation.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…